MedTrace Logo

Naltrexone in the Treatment of Dissociative Symptoms in Patients With Borderline Personality Disorder

NCT01133301 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2010-05-28

No results posted yet for this study

Summary

Our study aims at contributing to a valid appraisal of the magnitude of naltrexone efficacy as an antidissociative agent by using a double-blind randomized controlled trial.

Conditions

  • Borderline Personality Disorder
  • Dissociation

Interventions

DRUG

Naltrexone

50 mg/d Naltrexone will be administrated during three weeks.

DRUG

Placebo

During 3 weeks of the study, Placebo will be administrated (daily)

Sponsors & Collaborators

  • University of Freiburg

    collaborator OTHER

  • Central Institute of Mental Health, Mannheim

    lead OTHER

Principal Investigators

  • Christian Schmahl, MD · Central Institute of Mental Health, Dep. of Psychosomatic and Psychotherapeutic Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-08-31
Primary Completion
2001-08-31
Completion
2001-10-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01133301 on ClinicalTrials.gov